The business, which will be known as AbbVie, will be a research-based specialty biopharmaceuticals company with a broad portfolio of medicines, in areas including immunology and virology.
“Today’s announcement marks another important milestone toward the completion of our business separation,” said Miles D. White, chairman and CEO of Abbott, in the release. “Abbott and AbbVie are well-positioned to begin 2013 as leaders in their respective markets.”
Abbott is headquartered in Abbott Park, Ill.
Related Articles on Abbott:
Abbott Launches Drug Eluting Bioresorbable Vascular Scaffold
Abbott Receives FDA Clearance for Vascular Balloon-Expandable Stent System
Abbott Receives FDA Clearance for Cataract Surgery Protective Gel
